A fundamental question in oncology is how cancer cells evade programmed death mechanisms that would normally eliminate malignant cells. This biochemical investigation reveals a previously unknown pathway by which gastric cancer cells resist ferroptosis—an iron-dependent form of cellular suicide that represents a promising therapeutic target for treatment-resistant cancers.
The research demonstrates that the metabolic enzyme PFKFB4 becomes dramatically overexpressed in gastric cancer cells, where it performs a dual protective function. Beyond its established role in redirecting glucose metabolism to fuel tumor growth, PFKFB4 directly binds to and phosphorylates Heat Shock Protein Beta-1 (HSPB1), a molecular chaperone that suppresses ferroptotic cell death. This phosphorylation event effectively shields cancer cells from iron-mediated lipid peroxidation, allowing malignant cells to survive conditions that would normally trigger their destruction. Critically, when researchers treated cancer cells with 5MPN, a selective PFKFB4 inhibitor, the protective effect was abolished and ferroptosis sensitivity was restored.
This discovery illuminates why gastric cancer remains so therapeutically challenging despite recent treatment advances. The dual metabolic and anti-ferroptotic functions of PFKFB4 create a particularly robust survival advantage for cancer cells. From a translational perspective, targeting this PFKFB4-HSPB1 axis could represent a novel therapeutic strategy, especially for late-stage gastric cancers that have developed resistance to conventional therapies. However, the clinical utility will depend on whether this mechanism can be disrupted without causing excessive toxicity to normal cells, which also rely on ferroptosis regulation for tissue homeostasis. The findings suggest ferroptosis-inducing therapies may be most effective when combined with metabolic enzyme inhibitors.